Yahoo Finance

JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus

Johnson & Johnson JNJ announced that the phase IIb JASMINE study, which evaluated its pipeline candidate, nipocalimab, for treating adult patients with systemic lupus erythematosus (SLE), has met the ...
Seeking Alpha

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease ...
Morningstar

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity ...

SPRING HOUSE, Pa., Jan. 6, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic ...
Detroit News

Dr. Roach: Understanding how systemic lupus affects a person's body

Dear Dr. Roach: What is lupus, and what does it do to your body? I just had a friend diagnosed with it after many months of tests. — T.S.B. Dear T.S.B.: The term "lupus" generally means systemic lupus ...